ArticleCureus2025
Exceptional Response to Multimodal Therapy in Stage IV Pancreatic Ductal Adenocarcinoma: A Case Report and Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal prognosis, frequently presenting with metastatic disease that drives its lethality. Conventional chemotherapy offers limited survival benefits, prompting exploration of novel treatment strategies, including metastasis-directed therapies (MDT) for oligometastatic PDAC, characterized by a limited number of metastatic lesions. We describe a 74-year-old woman with KRAS G12D-mutated PDAC and 5 liver metastases, exceeding typical oligometastatic criteria (≤3 lesions). Systemic therapy with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (modified FOLFIRINOX), followed by maintenance fluorouracil, leucovorin, and irinotecan (FOLFIRI), led to a partial response that induced an oligometastatic state. She subsequently underwent a multimodal non-surgical treatment sequence involving percutaneous microwave ablation (MWA) for hepatic metastases and stereotactic body radiotherapy (SBRT) to the primary pancreatic tumor, achieving complete radiologic resolution of all lesions. This yielded an exceptional ongoing 20-month progression-free survival, remarkable for a KRAS G12D-mutated PDAC, a subtype known for its challenging clinical course. Our literature review suggests that MDT, including percutaneous ablation techniques and SBRT, may improve outcomes in oligometastatic PDAC by enhancing local control and potentially by eliciting systemic immune-mediated effects. This case highlights the transformative potential of integrating tailored MDT with chemotherapy to deliver outstanding outcomes in select patients with advanced PDAC, though further research is needed to refine patient selection and optimize therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.